Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA INCORPORATES PERSONAL WITNESS THEME: ADS, LEADERSHIP MESSAGE FOCUS ON PERSONAL STORIES; BRISTOL CHAIRMAN INVITES ABC's DONALDSON FOR FIRST-HAND VIEW

Executive Summary

Personal witness stories on the direct impact of pharmaceuticals on individuals are getting increased attention as part of the overall effort by the Pharmaceutical Research & Manufacturers of America to convey a message about the value of pharmaceuticals to the general public.

You may also be interested in...



PR Advice To PhRMA: More Communication And Communicate With Moore

The pharmaceutical industry should cooperate with documentary film maker Michael Moore, talk show host Larry King recommended during the Pharmaceutical Research & Manufacturers of America annual meeting March 18 in Washington, D.C

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

UsernamePublicRestriction

Register

PS029966

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel